Patients with cancer are more at risk of complications following heart procedure

November 30, 2018

Research led by Keele University suggests that patients with cancer who undergo a common heart procedure have worse short-term clinical outcomes compared to non-cancer patients, in the largest study undertaken to date.

The study, published today in the European Heart Journal, looked at 6.6 million hospital admissions in the USA over an 11-year period, in which the admitted patient underwent a percutaneous coronary intervention (PCI) procedure.

PCI is the most common interventional treatment undertaken in patients with coronary heart disease, and is a procedure in which a stent is used to open up narrowed or blocked blood vessels in the heart, both as a planned procedure or in the emergency heart attack setting.

Approximately 10% of the patients who underwent a PCI procedure during the 11-year period analysed had either a current or historical cancer diagnosis.

The study specifically looked at the impact on patients with a diagnosis of prostate, breast, colon or lung cancer, as these were the most prevalent in the dataset.

The study found that patients with a current diagnosis of lung cancer were three times more likely to die in hospital following a PCI procedure, compared to patients with no cancer. Colon cancer had the greatest association with major bleeding complications post-PCI, with a threefold increase compared to patients with no cancer. Patients with metastatic cancer, irrespective of cancer type, were found to have poorer outcomes following a PCI, and were at increased risk of dying in hospital, and suffering PCI complications, including major bleeding events.

Professor Mamas Mamas, Professor of Cardiology at Keele University who led the study commented:

"Our research found that a concurrent cancer diagnosis during these procedures is not uncommon, and it has an important impact on the clinical outcomes of these procedures, depending on the type of cancer, presence of metastases, and whether the diagnosis is historical or current.

"This research is important because there is limited data regarding outcomes of patients undergoing PCI with a current or historical diagnosis of cancer. Such patients are often excluded from randomised controlled trials, and cancer history is not captured in national PCI registries. Clinicians are often unsure what the risks of these procedures are in these patients, and how best the procedures should be undertaken."

Dr Jessica Potts, Research Associate at Keele University and co-author of the study, commented:

"Our recommendation is that treatment of patients with a cancer diagnosis should be individualised, recognising that cancer is associated with a higher risk of complications, and should involve a close collaboration between cardiologists and oncologists."
-end-


Keele University

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.